{"entity":{"id":"dmr-001","kind":"drug","name":"DMR-001","aka":[],"tldr":"DMR-001 is an experimental monoclonal antibody from Damora Therapeutics, in phase 1 trials for CALR-mutant essential thrombocythaemia and CALR-mutant myelofibrosis.","summary":"DMR-001 is a monoclonal antibody (subcutaneous, half-life extended) from Damora Therapeutics. An antibody designed to bind only mutant calreticulin (mutCALR), the driver of some myeloproliferative neoplasms, with half-life extension intended to allow infrequent subcutaneous dosing. Its furthest stage is phase 1, for CALR-mutant essential thrombocythaemia and CALR-mutant myelofibrosis. ClinicalTrials.gov registers it in one study linked below. Global phase 1/1b CLARITY-101 started mid-2026 (NCT07849231, recruiting). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Damora Therapeutics: damoratx.com","url":"https://damoratx.com/"},{"label":"Damora Therapeutics: damoratx.com","url":"https://damoratx.com/"},{"label":"Damora Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07849231"},{"label":"ClinicalTrials.gov: trials of DMR-001","url":"https://clinicaltrials.gov/search?intr=DMR-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["essential-thrombocythaemia","primary-myelofibrosis"],"sections":[],"technologies":[],"targets":["calr"],"drugs":[],"companies":["damora-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07849231"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DMR-001","modality":"Monoclonal antibody (subcutaneous, half-life extended)","mechanism":"An antibody designed to bind only mutant calreticulin (mutCALR), the driver of some myeloproliferative neoplasms, with half-life extension intended to allow infrequent subcutaneous dosing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dmr-001/","neighbours":{"cancer":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"target":[{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/"}],"company":[{"id":"damora-therapeutics","kind":"company","name":"Damora Therapeutics","route":"/companies/damora-therapeutics/"}],"trial":[{"id":"nct07849231","kind":"trial","name":"A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms","route":"/trials/nct07849231/"}]}}